JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Начало・Списък с акции・Cogent Biosciences Inc

Cogent Biosciences Inc

Затворен

12.08 -0.33

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.92

Максимум

12.13

Ключови измерители
By Trading Economics
Приходи	-4.1M -72M
Служители	205
EBITDA	-1.2M -74M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+62.72% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.1B 1.7B
Предишно отваряне	12.41
Предишно затваряне	12.08

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

4.88 / 5.87 Подкрепа & съпротива

Cogent Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.07.2025 г., 17:53 ч. UTC

Значими двигатели на пазара

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25.07.2025 г., 15:58 ч. UTC

Печалби

Значими двигатели на пазара

Aon Shares Rise After 2Q Earnings Beat

25.07.2025 г., 15:08 ч. UTC

Значими двигатели на пазара

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25.07.2025 г., 21:40 ч. UTC

Пазарно говорене

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25.07.2025 г., 21:23 ч. UTC

Пазарно говорене

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25.07.2025 г., 20:40 ч. UTC

Печалби

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25.07.2025 г., 20:10 ч. UTC

Печалби

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25.07.2025 г., 19:56 ч. UTC

Печалби

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25.07.2025 г., 19:14 ч. UTC

Пазарно говорене

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25.07.2025 г., 19:10 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25.07.2025 г., 19:01 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25.07.2025 г., 18:45 ч. UTC

Пазарно говорене

Gold Ends Down Week on Lower Note -- Market Talk

25.07.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

Sale Could Fetch Around $1B, Sources Say -- WSJ

25.07.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

LVMH in Talks to Sell Marc Jacobs -- WSJ

25.07.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25.07.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25.07.2025 г., 17:38 ч. UTC

Значими двигатели на пазара

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25.07.2025 г., 17:26 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Extends Decline -- Market Talk

25.07.2025 г., 17:13 ч. UTC

Печалби

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25.07.2025 г., 16:46 ч. UTC

Печалби

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25.07.2025 г., 16:45 ч. UTC

Печалби

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25.07.2025 г., 16:27 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

25.07.2025 г., 16:02 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25.07.2025 г., 15:34 ч. UTC

Печалби

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25.07.2025 г., 15:06 ч. UTC

Пазарно говорене

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25.07.2025 г., 15:05 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25.07.2025 г., 14:45 ч. UTC

Пазарно говорене

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25.07.2025 г., 14:44 ч. UTC

Пазарно говорене

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25.07.2025 г., 14:36 ч. UTC

Пазарно говорене

Печалби

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Cogent Biosciences Inc Прогноза

Ценова цел

By TipRanks

62.72% нагоре

12-месечна прогноза

Среден 19.64 USD 62.72%

Висок 29 USD

Нисък 9 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Cogent Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Cogent Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

4.88 / 5.87Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.